Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

<p>References used for filtering hits from drug screen</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Christopher T. Letson (16424095) (author)
Daljnji autori:	Maria E. Balasis (15033630) (author), Hannah Newman (15033618) (author), Moritz Binder (16424098) (author), Alexis Vedder (16424101) (author), Fumi Kinose (16424104) (author), Markus Ball (15033633) (author), Traci Kruer (15134201) (author), Ariel Quintana (16424107) (author), Terra L. Lasho (16424110) (author), Christy M. Finke (16424113) (author), Luciana L. Almada (16424116) (author), Jennifer M. Grants (16424119) (author), Guolin Zhang (15098544) (author), Martin E. Fernandez-Zapico (16424122) (author), Alexandre Gaspar-Maia (16424125) (author), Jeffrey Lancet (16424128) (author), Rami Komrokji (16424131) (author), Eric Haura (16424134) (author), David A. Sallman (15134216) (author), Gary W. Reuther (16424137) (author), Aly Karsan (15024852) (author), Uwe Rix (15040221) (author), Mrinal M. Patnaik (16424140) (author), Eric Padron (15134222) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Growth factors Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Translational Research
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
od: Yun-Guang Hong (14960966)
Izdano: (2025)

Figure 1 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 2 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 3 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 4 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 5 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 6 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Figure 7 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
od: Meng Li (79487)
Izdano: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
od: Shima Nakanishi (16336496)
Izdano: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
od: Shima Nakanishi (16336496)
Izdano: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
od: Yiming Wu (15306005)
Izdano: (2025)

Table S1 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S3 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S7 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Table S8 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
od: Xun-Xi Lu (14952883)
Izdano: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
od: Duygu Kuzuoglu-Ozturk (14960213)
Izdano: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
od: Cheng-Kai Wang (14963880)
Izdano: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fke7dd6gdt4n9l3llid8srm2ga